No Data
Perspective Draws Buy at Truist on Radiopharma Potential
MITEM PHARMA Acquires Worldwide Rights to DESFERAL (Deferoxamine) With the Backing of TECHLIFE CAPITAL and MACSF
Citi Sticks to Its Hold Rating for Novartis AG (NOVN)
Novartis AG Falls Tuesday, Underperforms Market
Generate:Biomedicines Announces Multi-Target Collaboration With Novartis to Discover and Develop Protein Therapeutics With Generative AI
UCB Gets Expanded FDA Approval for Psoriasis Drug Bimzelx
ひな☆彡 SOXL : You convinced me. I am happy to buy some later.
Growth Investor27 : Long ESPR $1.61 is very cheap.
Growth Investor27 : Long150,000 will hold for 5x upside for 2025 if not aquired.